

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

Brilliant Violet 605(TM) anti-human CD57 Recombinant

RRID:AB_2728425

Type: Antibody

Proper Citation

BioLegend Cat# 393303, RRID:AB_2728425

Antibody Information

URL: http://antibodyregistry.org/AB_2728425

Proper Citation: BioLegend Cat# 393303, RRID:AB_2728425

Target Antigen: CD57

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD57 Recombinant

Description: This recombinant monoclonal targets CD57

Target Organism: human

Clone ID: Clone QA17A04

Antibody ID: AB_2728425

Vendor: BioLegend

Catalog Number: 393303

Alternative Catalog Numbers: 393304

Record Creation Time: 20250819T210849+0000

Record Last Update: 20250819T220000+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD57 Recombinant.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD57 Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Munoz MA, et al. (2026) NK cell dysfunction and interferon- γ production underlie autoinflammation in mevalonate kinase deficiency. *Immunity*, 59(6), 1726.

Lupo KB, et al. (2023) TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. *iScience*, 26(12), 108353.

Scheer I, et al. (2023) Prospective Evaluation of CD45RA+/CCR7- Effector Memory T (TEMRA) Cell Subsets in Patients with Primary and Secondary Brain Tumors during Radiotherapy of the Brain within the Scope of the Prospective Glio-CMV-01 Clinical Trial. *Cells*, 12(4).